After more than 5 years in the top spot, Epizyme CEO Robert Gould is stepping down next month, leaving the company as it presses forward with a pair of promising cancer drugs.
Three years after stepping up with a $250 million deal--with $90 million upfront--Celgene has remapped its partnership with Epizyme, extending their collaboration three more years. Under this new deal, Cambridge, MA-based Epizyme gets $10 million cash with up to $610 million in milestones for three histone methyltransferase inhibitor targets.
Three months after retrieving rights to the lymphoma drug EPZ-6438 from Eisai in a $110 million deal, Epizyme has posted a positive glimpse at the drug's efficacy in a small, early-stage trial. And the news swiftly stoked the Cambridge, MA-based biotech's share price, which soared by 30% as investors pondered the possibilities.
Japan's Eisai sold the worldwide rights, excluding Japan, to Phase I/II cancer candidate EP-6438 to U.S.-based Epizyme for $40 million upfront, revising a 2011 agreement on discovery, development and commercialization of a therapy aimed at non-Hodgkin B-cell lymphoma and other cancers.
Pumped by the potential commercial impact of their EZH2 inhibitor EPZ-6438, Epizyme is dragging back global rights to the drug in what the Cambridge, MA-based biotech is calling a "transformative" deal.
After establishing itself as a biotech to watch in the field of epigenetics, Cambridge, MA-based Epizyme says it achieved some promising results in a preclinical trial of a new drug that marks the addition of a new target to its growing pipeline.
After recruiting a chief scientific officer from Epizyme, upstart cancer drug developer Loxo Oncology has nabbed a $24 million B round from some marquee venture players. New Enterprise Associates came in to lead this round, buying into the business plan of focusing on genetically-defined cancers, with existing investors Aisling Capital and OrbiMed Advisors joining in.
Shares of Cambridge, MA-based Epizyme jumped 10% this morning after the company announced that it had won a $4 million payment from GSK after hitting the third of the three histone methyltransferase targets in their collaboration.
Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...
After a slight lull in the biotech IPO arena, new offerings came barreling back this week with some fresh breakouts. In particular Foundation Medicine priced over the range and immediately soared more than 80%. And Ophthotech also crested its range, erasing any lingering doubts about the short-term sustainability of the biotech IPO frenzy. Together they raised $273 million in a 24-hour pop. Read the report >>